Probiotics Prevent Hepatic Encephalopathy in Patients With Cirrhosis: A Randomized Controlled Trial

被引:137
|
作者
Lunia, Manish Kumar [1 ]
Sharma, Barjesh Chander [1 ]
Sharma, Praveen [1 ]
Sachdeva, Sanjeev [1 ]
Srivastava, Siddharth [1 ]
机构
[1] GB Pant Hosp, Dept Gastroenterol, New Delhi 110002, India
关键词
Cognitive and Motor Function; Treatment; Therapy; Clinical Trial; MHE; INTESTINAL BACTERIAL OVERGROWTH; CRITICAL FLICKER FREQUENCY; OPEN-LABEL; FRUCTO-OLIGOSACCHARIDE; SECONDARY PROPHYLAXIS; TRANSIT-TIME; GUT FLORA; LACTULOSE; METAANALYSIS; MODULATION;
D O I
10.1016/j.cgh.2013.11.006
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Hepatic encephalopathy (HE) is associated with a poor prognosis in patients with advanced liver disease. Probiotics alter the intestinal microbiota with non-urease- producing organisms that reduce production of ammonia. We investigated the efficacy of probiotics for the primary prophylaxis of HE. METHODS: We conducted a prospective trial at a tertiary care referral institute in New Delhi, India, from January 2012 through March 2013, of patients with cirrhosis without overt HE (age, 48.6 +/- 11.1 y; 96 men and 64 women); 25 were Child-Turcotte-Pugh (CTP) class A, 51 were CTP class B, and 84 were CTP class C. Subjects were assigned randomly to groups given probiotics (1 x 10(8) colony-forming units, 3 times daily; n = 86, 42 with minimal HE) or no test article (control, n = 74; 33 with minimal HE). All subjects underwent psychometric analyses, critical flicker fusion (CFF) threshold assessments, glucose hydrogen breath tests to identify small intestinal bacterial overgrowth (SIBO), and lactulose hydrogen breath tests to measure orocecal transit time (OCTT). The primary end point was the development of overt HE. RESULTS: At baseline, subjects in each group had comparable CTP score, model for end-stage liver disease scores, CFF assessments, psychometric hepatic encephalopathy scores, and OCTT. After a mean follow-up period of 38.6 +/- 8.80 weeks for patients given probiotics and 40.3 +/- 9.8 weeks for controls, 6 patients given probiotics and 7 controls died (P = .81). Three months of probiotic administration significantly reduced levels of arterial ammonia, SIBO, and OCTT; increased psychometric hepatic encephalopathy scores; and increased CFF thresholds, compared with baseline. Seven subjects in the probiotic group and 14 controls developed overt HE (P < .05; hazard ratio for controls vs probiotic group, 2.1; 95% confidence interval, 1.31-6.53). Psychometric hepatic encephalopathy scores, CTP scores, and SIBO correlated with the development of overt HE. CONCLUSIONS: In a prospective, randomized controlled trial, probiotics were found to be effective in preventing HE in patients with cirrhosis.
引用
收藏
页码:1003 / +
页数:7
相关论文
共 50 条
  • [1] AN OPEN LABEL RANDOMISED CONTROLLED TRIAL OF PROBIOTICS FOR PRIMARY PROPHYLAXIS OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS
    Lunia, M. K.
    Sharma, B. C.
    Sachdeva, S.
    Srivastava, S.
    [J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S35 - S35
  • [2] An open label randomised controlled trial of probiotics for primary prophylaxis of hepatic encephalopathy in patients with cirrhosis
    Lunia, Manish Kumar
    Sachdeva, Sanjeev
    Srivastava, Siddharth
    Sharma, Brijesh Chander
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 241 - 241
  • [3] Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open-Label, Randomized Controlled Trial of Lactulose, Probiotics, and No Therapy
    Agrawal, Amit
    Sharma, Barjesh Chander
    Sharma, Praveen
    Sarin, Shiv Kumar
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (07): : 1043 - 1050
  • [4] Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open label, randomized controlled trial of lactulose, probiotics and no-therapy
    Agrawal, A.
    Sharma, B. C.
    Sharma, P.
    Sarin, S. K.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 7 - 7
  • [5] Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open Label, Randomized Controlled Trial of Lactulose, Probiotics and No-therapy
    Nazir, Sharique
    Lau, Kwan
    Sindram, David
    Martinie, John
    Asarian, Armand
    Iannitti, David
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S105 - S105
  • [6] SECONDARY PROPHYLAXIS OF HEPATIC ENCEPHALOPATHY IN CIRRHOSIS: AN OPEN LABEL, RANDOMIZED CONTROLLED TRIAL OF LACTULOSE, PROBIOTICS AND NO-THERAPY
    Agrawal, Amit
    Sharma, Barjesh
    Sharma, Praveen
    Sarin, Shiv K.
    [J]. HEPATOLOGY, 2011, 54 : 1248A - 1248A
  • [7] An Open-Label Randomized Trial of Lactulose and Probiotics in the Treatment of Hepatic Encephalopathy in Patients With Liver Cirrhosis
    Yusuf, Fauzi
    Abubakar, Azzaki
    Wahyuni, Wahyuni
    Irawan, Ganis
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S876 - S877
  • [8] A randomized control trial of lactulose versus probiotics versus lactulose plus probiotics in the treatment of minimal hepatic encephalopathy of cirrhosis
    Sharma, Praveen
    Sharma, B. C.
    Puri, Vinod
    Sarin, S. K.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S178 - S178
  • [9] An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy
    Sharma, Praveen
    Sharma, Barjesh C.
    Puri, Vinod
    Sarin, Shiv Kumar
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2008, 20 (06) : 506 - 511
  • [10] Efficacy of Nutritional Therapy for Patients With Cirrhosis and Minimal Hepatic Encephalopathy in a Randomized Trial
    Maharshi, Sudhir
    Sharma, Barjesh Chander
    Sachdeva, Sanjeev
    Srivastava, Siddharth
    Sharma, Praveen
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (03) : 454 - +